Approval over the pond, Bristol Myers Squibb gains EU approval for Opdivo combination in lymphoma Bristol Myers Squibb (BMY) received European Commission approval for Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for treating...
